Rockwell Medical Inc

NASDAQ:RMTI  
0.40
-0.07 (-14.02%)
Products

Rockwell Medical Receives Important Feedback From FDA On Its Ind Application For Phase 2 Trial Of Ferric Pyrophosphate Citrate In Home Infusion

Published: 12/14/2021 14:29 GMT
Rockwell Medical Inc (RMTI) - Rockwell Medical Receives Important Feedback From FDA on Its Ind Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion.
Rockwell Medical Receives Important Feedback From FDA on Its Ind Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion.
Rockwell Medical- FDA Requested Additional Data for Microbiology, Short-term Stability of Fpc to Support Drug Administration Method Proposed for Study.
Rockwell Medical Inc - Company Expects to Run These Additional Studies, Complete Required Analysis, and Provide Requested Data in First Half of 2022.
Rockwell Medical Inc - Once Additional Data is Submitted, Rockwell Must Wait 30 Calendar Days Before Treating Any Patients in Clinical Trial.